证券代码：600518 证券简称：康美药业 编号：临2025-029 康美药业股份有限公司 关于全资子公司被申请破产清算的结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 广东省高级人民法院裁定驳回佛山市翔盈家具制造有限公司提起的申请 康美中药城（普宁）有限公司破产清算的上诉请求，维持原裁定。 康美药业股份有限公司（以下简称公司）全资子公司康美中药城（普宁）有 限公司（以下简称普宁中药城或被上诉人）近日收到广东省高级人民法院（以下 简称广东高院）送达的《民事裁定书》，广东高院裁定驳回佛山市翔盈家具制造 有限公司（以下简称翔盈公司或上诉人）提起的申请普宁中药城破产清算的上诉 请求，现将相关情况公告如下： 一、普宁中药城被申请破产清算的基本情况 公司于 2024 年 3 月 13 日披露了《康美药业关于全资子公司被申请破产清算 的提示性公告》（公告编号：临 2024-006），公司下属全资子公司康美中药城 （普宁）有限公司的债权人佛山市翔盈家具制造有限公司以普宁中药城无法清偿 到期债务为由，向广东省揭阳市中 ...

Group 1 - The stock price of Kangmei Pharmaceutical is reported at 2.07 yuan, unchanged from the previous trading day, with a highest intraday price of 2.10 yuan and a lowest of 2.06 yuan, and a trading volume of 2.0569 million shares, amounting to 427 million yuan, with a fluctuation of 1.93% [1] - Kangmei Pharmaceutical operates in the traditional Chinese medicine industry, primarily engaged in the research, development, production, and sales of traditional Chinese medicine pieces, chemical drugs, and other products, covering various fields including Chinese medicinal materials, traditional Chinese medicine pieces, and Western drug formulations [1] - On August 12, the net outflow of main funds was 11.5782 million yuan, accounting for 0.04% of the circulating market value. Over the past five trading days, the cumulative net outflow reached 82.5904 million yuan, representing 0.29% of the circulating market value [1]

Policy Developments - The National Medical Products Administration (NMPA) has released a draft for public consultation regarding the adjustment of medical device classifications, aiming to optimize the registration and filing requirements for medical devices [1] Drug Approval - Yuyuan Pharmaceutical's YKYY029 injection has received clinical trial approval for treating hypertension, marking a significant step in the development of a novel siRNA drug [2] - Hengrui Medicine has received clinical trial approvals for four drugs, including SHR-8068 injection and Abediterib injection, with total R&D investments amounting to approximately 20.33 million yuan [3] Financial Reports - Microchip Biotech expects a net profit of 30.06 million yuan for the first half of 2025, driven by increased sales from new drug listings and optimized sales strategies [4] - China National Pharmaceutical Modern reported a 6.46% decline in net profit for the first half of the year, attributed to decreased sales and prices of certain antibiotics and other products [5] Capital Market - Tigermed announced the sale of its stake in Lixin Pharmaceutical for approximately 34.11 million USD, reflecting a strategic move in the context of the domestic pharmaceutical industry's consolidation [6] Industry Events - A breakthrough in brain-computer interface technology has been achieved in Shanghai, allowing patients with speech impairments to communicate through decoded brain activity [8] - Yuan Da Pharmaceutical's innovative nasal spray for dry eye treatment has received approval and its first prescriptions have been issued, providing a new treatment option for patients [9] Debt Resolution - Kangmei Pharmaceutical has reached a settlement agreement to resolve historical debt issues for 43.5 million yuan, facilitating the closure of related legal matters [10] Market Sentiment - Weier Pharmaceutical announced plans for its employee stock ownership platform to reduce its holdings by up to 1% of the company's shares, driven by shareholder funding needs [11]

Group 1 - The board of directors of Kangmei Pharmaceutical Co., Ltd. held its third temporary meeting of the 2025 fiscal year on July 16, 2025, with all nine directors present, ensuring compliance with relevant laws and regulations [1][2] - The board approved a resolution regarding the signing of a settlement agreement and related party transactions, with a voting result of 6 in favor, 0 against, and 0 abstentions, while related directors recused themselves from the vote [1]

证券代码：600518 证券简称：康美药业 编号：临2025-028 康美药业股份有限公司 关于下属公司签订和解协议暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易简要内容：为有序推进案件结案，公司全资下属二级子公司成都康美 药业生产有限公司（以下简称成都康美）拟与广州医药集团有限公司（以下简称 广药集团）签订和解协议，约定以 4,350 万元及相关手续费等对前述债务进行清 偿，款项支付完毕后，由广药集团协助成都康美办理执行解封及结案等手续。 本次交易构成关联交易。 本次交易未构成重大资产重组。 康美药业股份有限公司（以下简称康美药业或公司）与广州资产管理有限公 司（以下简称广州资产）存在历史债务纠纷，公司全资下属二级子公司成都康美 对前述 4,939.11 万元债务提供抵押担保。广东省高级人民法院于 2023 年 11 月 作出（2022）粤民终 3992 号《民事判决书》，成都康美需对康美药业所负前述 债务承担抵押责任，后广州资产向法院申请强制执行。近期，广州资产在阿里平 台公开拍卖前 ...

证券代码：600518 证券简称：康美药业 编号：临2025-027 （一）审议通过《关于孙公司签订和解协议暨关联交易的议案》 表决结果：赞同票 6 票，反对票 0 票，弃权票 0 票，关联董事赖志坚先生、 欧国雄先生、周云峰先生回避表决。 本议案经独立董事专门会议审议通过。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《康美药业关于下属公司签订和解协议暨关联交易的公告》。 特此公告。 康美药业股份有限公司 第十届董事会 2025 年度第三次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 康美药业股份有限公司（以下简称公司）第十届董事会 2025 年度第三次临 时会议于 2025 年 7 月 16 日以现场结合通讯表决方式召开，会议通知已于 2025 年 7 月 9 日以通讯、邮件方式向公司各位董事发出。本次会议应当出席董事 9 名，实际出席董事 9 名，董事长赖志坚先生主持会议，公司全体监事列席会议， 本次会议的召开符合《公司法》《公司章程》等相 ...

Core Viewpoint - Kangmei Pharmaceutical plans to sign a settlement agreement with its affiliate Guangzhou Pharmaceutical Group to resolve historical debt issues for 43.5 million yuan [1] Group 1 - The subsidiary Chengdu Kangmei Pharmaceutical intends to pay 43.5 million yuan along with related fees to settle the debt [1] - After the payment is completed, Guangzhou Pharmaceutical Group will assist Chengdu Kangmei in handling the execution unsealing and case closure procedures [1] - This transaction is classified as a related party transaction but does not constitute a major asset restructuring [1]

Group 1 - As of July 9, the total market financing balance reached 1.86 trillion yuan, an increase of 3.84 billion yuan from the previous trading day, marking three consecutive days of growth [1] - The financing balance for the Shanghai Stock Exchange was 932.96 billion yuan, up by 1.88 billion yuan, while the Shenzhen Stock Exchange's balance was 916.86 billion yuan, increasing by 1.96 billion yuan [1] - A total of 1,875 stocks experienced net financing inflows on July 9, with 434 stocks having net inflows exceeding 10 million yuan, and 11 stocks exceeding 100 million yuan [1] Group 2 - The top net financing inflow was seen in Zijin Mining, with a net inflow of 310 million yuan, followed by Luoyang Molybdenum and Dongshan Precision, with net inflows of 228 million yuan and 167 million yuan, respectively [2] - In terms of industry distribution, the sectors with significant net inflows included non-ferrous metals, electric equipment, and pharmaceutical biology, with three, two, and two stocks respectively [1][2] - The average ratio of financing balance to circulating market value for stocks with large net inflows was 3.28%, with Jin Kai New Energy having the highest ratio at 8.52% [2]

Market Overview - On July 9, the Shanghai Composite Index fell by 0.13%, the Shenzhen Component Index decreased by 0.06%, while the ChiNext Index rose by 0.16%. The CSI 300 Index declined by 0.18% [1] - Among the tradable A-shares, 1,856 stocks rose, accounting for 34.33%, while 3,327 stocks fell [1] Capital Flow - The main capital saw a net outflow of 38.536 billion yuan throughout the day. The ChiNext experienced a net outflow of 13.082 billion yuan, the STAR Market saw a net outflow of 3.036 billion yuan, and the CSI 300 constituents had a net outflow of 7.698 billion yuan [1] - Only three industries saw net inflows of capital: Media industry with a rise of 1.35% and a net inflow of 1.055 billion yuan; Retail industry with a rise of 0.48% and a net inflow of 0.864 billion yuan; and Construction Decoration industry with a rise of 0.37% and a net inflow of 4.034 million yuan [1] Industry Performance - Among the 28 industries that experienced net outflows, the Electronics industry had the largest outflow, declining by 0.82% with a net outflow of 7.789 billion yuan. The Non-ferrous Metals industry followed with a decline of 2.26% and a net outflow of 5.412 billion yuan [1] - The top-performing industries included Media and Agriculture, Forestry, Animal Husbandry, and Fishery, with increases of 1.35% and 0.65%, respectively. The worst-performing industries were Non-ferrous Metals and Basic Chemicals, with declines of 2.26% and 0.85% [1] Individual Stock Performance - A total of 1,686 stocks saw net inflows, with 524 stocks having inflows exceeding 10 million yuan. Notably, 57 stocks had inflows exceeding 100 million yuan, with Kuaijingtong leading at an increase of 10.10% and a net inflow of 896 million yuan [2] - The stocks with the largest net outflows included Zhongyou Capital, Dongfang Caifu, and Zijin Mining, with outflows of 721 million yuan, 706 million yuan, and 625 million yuan, respectively [2]

Core Viewpoint - The legal opinion letter from Guangdong Xinda Law Firm confirms that Kangmei Pharmaceutical Co., Ltd.'s plan to repurchase and cancel unvested restricted stocks under its first and second stock incentive plans complies with relevant laws and regulations [4][6][8]. Summary by Sections Repurchase and Cancellation Conditions - The decision to terminate the first and second stock incentive plans and repurchase unvested restricted stocks is based on the provisions of the Management Measures and has been approved by the company's board and shareholders [4][6]. Decision-Making Process and Information Disclosure - On September 14, 2021, the company held meetings to approve the termination of the first and second stock incentive plans and the repurchase of unvested stocks, with independent directors expressing agreement [6][7]. - The company disclosed the resolutions through official announcements [7]. Involved Parties, Share Quantity, and Cancellation Date - The repurchase involves 816 incentive recipients [8]. - The total number of shares to be repurchased and canceled is 34.97 million shares [8]. - The company has applied for the necessary procedures with the China Securities Depository and Clearing Corporation [8]. Conclusion - The legal opinion concludes that the repurchase and cancellation process meets all necessary legal and regulatory requirements [8].